Bellicum Pharmaceuticals (NASDAQ:BLCM) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Wednesday. The brokerage presently has a $10.00 price objective on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 12.87% from the company’s previous close.
According to Zacks, “Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company’s lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. “
Several other analysts have also issued reports on BLCM. BidaskClub upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, January 4th. ValuEngine upgraded shares of Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, January 3rd. Raymond James Financial restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 12th. Finally, Jefferies Group restated a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a research report on Thursday, September 14th. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $23.50.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.03. The company had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.03 million. During the same quarter last year, the firm posted ($0.66) earnings per share. The firm’s revenue was up 18.2% on a year-over-year basis. equities analysts predict that Bellicum Pharmaceuticals will post -2.93 earnings per share for the current fiscal year.
In related news, CFO Alan A. Musso sold 17,117 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $9.33, for a total value of $159,701.61. Following the completion of the transaction, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at $294,688.05. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Alan A. Musso sold 6,206 shares of the stock in a transaction dated Monday, November 27th. The stock was sold at an average price of $9.89, for a total transaction of $61,377.34. The disclosure for this sale can be found here. Corporate insiders own 18.77% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in Bellicum Pharmaceuticals by 10.2% in the second quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock worth $28,811,000 after buying an additional 227,668 shares in the last quarter. Vanguard Group Inc. raised its stake in Bellicum Pharmaceuticals by 13.6% in the second quarter. Vanguard Group Inc. now owns 1,206,436 shares of the biopharmaceutical company’s stock worth $14,092,000 after buying an additional 144,854 shares in the last quarter. State Street Corp raised its stake in Bellicum Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock worth $4,872,000 after buying an additional 59,321 shares in the last quarter. Point72 Asset Management L.P. bought a new position in Bellicum Pharmaceuticals in the third quarter worth about $4,723,000. Finally, Northern Trust Corp raised its stake in Bellicum Pharmaceuticals by 29.5% in the second quarter. Northern Trust Corp now owns 341,555 shares of the biopharmaceutical company’s stock worth $3,989,000 after buying an additional 77,760 shares in the last quarter. 55.28% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: “Bellicum Pharmaceuticals (BLCM) Lifted to Buy at Zacks Investment Research” was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.themarketsdaily.com/2018/01/10/bellicum-pharmaceuticals-blcm-lifted-to-buy-at-zacks-investment-research.html.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.